The Journal of Nuclear Medicine最新文献

{"title":"Design, Synthesis, and Preclinical Evaluation of a High-Affinity 18F-Labeled Radioligand for Myocardial Growth Hormone Secretagogue Receptor Before and After Myocardial Infarction","authors":"Rebecca Sullivan, Jinqiang Hou, Lihai Yu, Benjamin Wilk, Jane Sykes, Heather Biernaski, John Butler, Michael Kovacs, Justin Hicks, Jonathan D. Thiessen, Rohan Dharmakumar, Frank S. Prato, Gerald Wisenberg, Leonard G. Luyt, Savita Dhanvantari","doi":"10.2967/jnumed.124.267578","DOIUrl":"https://doi.org/10.2967/jnumed.124.267578","url":null,"abstract":"<p>The peptide hormone ghrelin is produced in cardiomyocytes and acts through the myocardial growth hormone secretagogue receptor (GHSR) to promote cardiomyocyte survival. Administration of ghrelin may have therapeutic effects on post–myocardial infarction (MI) outcomes. Therefore, there is a need to develop molecular imaging probes that can track the dynamics of GHSR in health and disease to better predict the effectiveness of ghrelin-based therapeutics. We designed a high-affinity GHSR ligand labeled with ¹⁸F for imaging by PET and characterized its in vivo properties in a canine model of MI. <strong>Methods:</strong> We rationally designed and radiolabeled with ¹⁸F a quinazolinone derivative ([¹⁸F]LCE470) with subnanomolar binding affinity to GHSR. We determined the sensitivity and in vivo and ex vivo specificity of [¹⁸F]LCE470 in a canine model of surgically induced MI using PET/MRI, which allowed for anatomic localization of tracer uptake and simultaneous determination of global cardiac function. Uptake of [¹⁸F]LCE470 was determined by time–activity curve and SUV analysis in 3 regions of the left ventricle—area of infarct, territory served by the left circumflex coronary artery, and remote myocardium—over a period of 1.5 y. Changes in cardiac perfusion were tracked by [¹³N]NH₃ PET. <strong>Results:</strong> The receptor binding affinity of LCE470 was measured at 0.33 nM, the highest known receptor binding affinity for a radiolabeled GHSR ligand. In vivo blocking studies in healthy hounds and ex vivo blocking studies in myocardial tissue showed the specificity of [¹⁸F]LCE470, and sensitivity was demonstrated by a positive correlation between tracer uptake and GHSR abundance. Post-MI changes in [¹⁸F]LCE470 uptake occurred independently of perfusion tracer distributions and changes in global cardiac function. We found that the regional distribution of [¹⁸F]LCE470 within the left ventricle diverged significantly within 1 d after MI and remained that way throughout the 1.5-y duration of the study. <strong>Conclusion:</strong> [¹⁸F]LCE470 is a high-affinity PET tracer that can detect changes in the regional distribution of myocardial GHSR after MI. In vivo PET molecular imaging of the global dynamics of GHSR may lead to improved GHSR-based therapeutics in the treatment of post-MI remodeling.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors","authors":"Andrea Galbiati, Matilde Bocci, Domenico Ravazza, Jacqueline Mock, Ettore Gilardoni, Dario Neri, Samuele Cazzamalli","doi":"10.2967/jnumed.124.268200","DOIUrl":"https://doi.org/10.2967/jnumed.124.268200","url":null,"abstract":"<p>Fibroblast activation protein (FAP) is abundantly expressed in the stroma of most human solid tumors. Clinical-stage radiolabeled FAP ligands are increasingly used as tools for the detection of various cancer lesions. To unleash the full therapeutic potential of FAP-targeting agents, ligands need to remain at the tumor site for several days after administration. We recently described the discovery of OncoFAP, a high-affinity small organic ligand of FAP with a rapid accumulation in tumors and low uptake in healthy tissues in cancer patients. Trimerization of OncoFAP provided a derivative (named TriOncoFAP, or OncoFAP-23) with improved FAP affinity. In this work, we evaluated the tissue biodistribution profile and the therapeutic performance of OncoFAP-23 in tumor-bearing mice. <strong>Methods:</strong> OncoFAP-23 was radiolabeled with the theranostic radionuclide ¹⁷⁷Lu. Preclinical experiments were conducted on mice bearing SK-RC-52.hFAP (BALB/c nude mice) or CT-26.hFAP (BALB/c mice) tumors. ¹⁷⁷Lu-OncoFAP and ¹⁷⁷Lu-FAP-2286 were included in the biodistribution study as controls. Toxicologic evaluation was performed on Wistar rats and CD1 mice by injecting high doses of OncoFAP-23 or its cold-labeled counterpart, respectively. <strong>Results:</strong> ¹⁷⁷Lu-OncoFAP-23 emerged for its best-in-class biodistribution profile, high and prolonged tumor uptake (i.e., ∼16 percentage injected dose/g at 96 h), and low accumulation in healthy organs, which correlates well with its potent single-agent anticancer activity at low levels of administered radioactivity. Combination treatment with the tumor-targeted interleukin 2 (L19-IL2, a clinical-stage immunocytokine) further expands the therapeutic window of ¹⁷⁷Lu-OncoFAP-23 by potentiating its in vivo antitumor activity. Proteomics studies revealed a potent tumor-directed immune response on treatment with the combination. OncoFAP-23 and ^natLu-OncoFAP-23 exhibited a favorable toxicologic profile, without showing any side effects or signs of toxicity. <strong>Conclusion:</strong> OncoFAP-23 presents enhanced tumor uptake and tumor retention and low accumulation in healthy organs, findings that correspond to a strongly improved in vivo antitumor efficacy. The data presented in this work support the clinical development of ¹⁷⁷Lu-OncoFAP-23 for the treatment of FAP-positive solid tumors.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Imaging of p53 in Mouse Models of Cancer Using a Radiolabeled Antibody TAT Conjugate with SPECT","authors":"Hudson Alakonya, Sofia Koustoulidou, Samantha L. Hopkins, Mathew Veal, Javier Ajenjo, Deborah Sneddon, Gemma Dias, Michael Mosley, Julia Baguña Torres, Francesca Amoroso, Amanda Anderson, Alison H. Banham, Bart Cornelissen","doi":"10.2967/jnumed.124.267736","DOIUrl":"https://doi.org/10.2967/jnumed.124.267736","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.267736absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for 161Tb Compared with 177Lu with a Higher Dose Response for [161Tb]Tb-DOTA-LM3 Than for [161Tb]Tb-DOTATATE","authors":"Kaat Spoormans, Lara Struelens, Koen Vermeulen, Marijke De Saint-Hubert, Michel Koole, Melissa Crabbé","doi":"10.2967/jnumed.124.267873","DOIUrl":"https://doi.org/10.2967/jnumed.124.267873","url":null,"abstract":"&lt;p&gt;Preclinical data have shown that &lt;sup&gt;161&lt;/sup&gt;Tb-labeled peptides targeting the somatostatin receptor are therapeutically more effective for peptide receptor radionuclide therapy than are their &lt;sup&gt;177&lt;/sup&gt;Lu-labeled counterparts. To further substantiate this enhanced therapeutic effect, we performed cellular dosimetry to quantify the absorbed dose to the cell nucleus and compared dose–response curves to evaluate differences in relative biological effectiveness in vitro. &lt;strong&gt;Methods:&lt;/strong&gt; CA20948 cell survival was assessed after treatment with [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb- and [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-DOTATATE (agonist) and with [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb- and [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-DOTA-LM3 (antagonist) via a clonogenic assay. Cell binding, internalization, and dissociation assays were performed up to 7 d to acquire time-integrated activity coefficients. Separate &lt;em&gt;S&lt;/em&gt; values for each type of particle emission (Auger/internal conversion [IC] electrons and β&lt;sup&gt;−&lt;/sup&gt; particles) were computed via Monte Carlo simulations, while considering spheric cells. Once the absorbed dose to the cell nucleus was calculated, survival curves were fitted to the appropriate linear or linear-quadratic model and corresponding relative biological effectiveness was evaluated. &lt;strong&gt;Results:&lt;/strong&gt; Although the radiopeptide uptake was independent of the radionuclide, [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTATATE and [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTA-LM3 delivered a 3.6 and 3.8 times higher dose to the nucleus, respectively, than their &lt;sup&gt;177&lt;/sup&gt;Lu-labeled counterparts on saturated receptor binding. This increased nucleus-absorbed dose was mainly due to the additional emission of IC and not Auger electrons by &lt;sup&gt;161&lt;/sup&gt;Tb. When activity concentrations were considered, both [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTATATE and [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTA-LM3 showed a lower survival fraction than did labeling with &lt;sup&gt;177&lt;/sup&gt;Lu. When the absorbed dose to the nucleus was considered, no significant difference could be observed between the dose–response curves for [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb- and [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-DOTATATE. [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTA-LM3 showed a linear-quadratic dose response, whereas [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTATATE showed only a linear dose response within the observed dose range, suggesting additional cell membrane damage by Auger electrons. &lt;strong&gt;Conclusion:&lt;/strong&gt; The IC, rather than Auger, electrons emitted by &lt;sup&gt;161&lt;/sup&gt;Tb resulted in a higher absorbed dose to the cell nucleus and lower clonogenic survival for [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTATATE and [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTA-LM3 than for the &lt;sup&gt;177&lt;/sup&gt;Lu-labeled analogs. In contrast, [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTATATE showed no higher dose response than [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-DOTATATE, whereas for [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTA-LM3 an additional quadratic response was observed. Because of this quadratic response, potentially caused by cell membrane damage, [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTA-LM3 is a more effective radiopeptide than [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142100847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between CA 15-3 and 18F-FDG PET/CT Findings in Recurrent Breast Cancer Patients at a Tertiary Referral Hospital in Kenya","authors":"Margaret M. Mwania, Samuel Nguku Gitau, Jasmit Shah, Khalid Makhdomi","doi":"10.2967/jnumed.124.267851","DOIUrl":"https://doi.org/10.2967/jnumed.124.267851","url":null,"abstract":"<p>The tumor marker cancer antigen 15-3 (CA 15-3) is that most commonly used to monitor metastatic breast cancer during active therapy and surveillance for disease recurrence after treatment. The association of CA 15-3 and ¹⁸F-FDG PET/CT findings can be considered complementary, since any significant rise may indicate the presence of disease and imaging is able to map the tumor sites. Although current guidelines do not recommend the routine performance of CA 15-3 in asymptomatic patients being followed up after definitive breast cancer treatment, most oncologists perform serial assessment of the tumor markers as part of routine follow-up of patients. The aim of this study was to evaluate the correlation between CA 15-3 levels and ¹⁸F-FDG PET/CT scan findings in patients with recurrent breast cancer. <strong>Methods:</strong> This was a cross-sectional study with data collected retrospectively. Patients being evaluated for breast cancer recurrence with ¹⁸F-FDG PET/CT imaging and CA 15-3 level were included. Evaluation of the association between CA 15-3 levels and ¹⁸F-FDG PET/CT scan findings was then done. <strong>Results:</strong> In total, 154 cases were included in this study; 62 patients had recurrence (positive) on the ¹⁸F-FDG PET/CT scans, whereas 92 patients had normal (negative) findings on follow-up ¹⁸F-FDG PET/CT scans. There was an association between CA 15-3 levels and the presence or absence of recurrence on ¹⁸F-FDG PET/CT scans, with 84.4% (27/32) of patients who had elevated CA 15-3 levels having disease recurrence on ¹⁸F-FDG PET/CT and 84.4% (27/32) of patients who had elevated CA 15-3 levels having disease recurrence on ¹⁸F-FDG PET/CT as well as a correlation with the burden of metastases. Most patients with disease recurrence on ¹⁸F-FDG PET/CT, however, had normal CA 15-3 levels. <strong>Conclusion:</strong> Higher CA 15-3 levels correlate with breast cancer recurrence on ¹⁸F-FDG PET/CT as well as with burden of metastasis. Notably, CA 15-3 levels within the reference range do not exclude breast cancer disease recurrence since more than half of patients with recurrence had normal CA 15-3 levels. ¹⁸F-FDG PET/CT should therefore be considered in patients with suspected breast cancer recurrence but normal CA 15-3 levels.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142100750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving 18F-FDG PET Quantification Through a Spatial Normalization Method","authors":"Daewoon Kim, Seung Kwan Kang, Seong A. Shin, Hongyoon Choi, Jae Sung Lee","doi":"10.2967/jnumed.123.267360","DOIUrl":"https://doi.org/10.2967/jnumed.123.267360","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.123.267360absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142100753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of 18F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE","authors":"Virginie Combet-Curt, Chloé Buchalet, Karine Le Malicot, Claire Lemanski, Emmanuel Deshayes, Nathalie Bonichon-Lamichhane, Astrid Lièvre, Florence Huguet, Ghoufrane Tlili, Véronique Vendrely","doi":"10.2967/jnumed.124.267626","DOIUrl":"https://doi.org/10.2967/jnumed.124.267626","url":null,"abstract":"<p>This study aimed to evaluate the prognostic value of ¹⁸F-FDG PET/CT qualitative assessment in terms of recurrence-free survival (RFS), colostomy-free survival (CFS), and overall survival (OS) after radiation therapy (RT) of squamous cell carcinoma of the anus (SCCA). Secondary objectives were to evaluate the prognostic value of baseline and posttherapeutic quantitative ¹⁸F-FDG PET/CT parameters in terms of RFS, CFS, and OS. <strong>Methods:</strong> We included all consecutive patients from the French multicentric cohort FFCD-ANABASE who had undergone ¹⁸F-FDG PET/CT at baseline and 4–6 mo after RT or chemoradiotherapy for a localized SCCA. Qualitative assessments separated patients with complete metabolic response (CMR) and non-CMR. Quantitative parameters were measured on baseline and posttreatment ¹⁸F-FDG PET/CT. RFS, CFS, and OS were analyzed using the Kaplan–Meier method. Associations among qualitative assessments, quantitative parameters, and RFS, CFS, and OS were analyzed using univariate and multivariate Cox regression. <strong>Results:</strong> Among 1,015 patients treated between January 2015 and April 2020, 388 patients (300 women and 88 men) from 36 centers had undergone ¹⁸F-FDG PET/CT at diagnosis and after treatment. The median age was 65 y (range, 32–90 y); 147 patients (37.9%) had an early-stage tumor and 241 patients (62.1%) had a locally advanced-stage tumor; 59 patients (15.2%) received RT, and 329 (84.8%) received chemoradiotherapy. The median follow-up was 35.5 mo (95% CI, 32.8–36.6 mo). Patients with CMR had better 3-y RFS, CFS, and OS, at 84.2% (95% CI, 77.8%–88.9%), 84.7% (95% CI, 77.2%–89.3%), and 88.6% (95% CI, 82.5%–92.7%), respectively, than did non-CMR patients, at 42.1% (95% CI, 33.4%–50.6%), 47.9% (95% CI, 38.1%–56.8%), and 63.5 (95% CI, 53.2%–72.1%), respectively (<em>P</em> &lt; 0.0001). Quantitative parameters were available for 154 patients from 3 centers. The following parameters were statistically significantly associated with 3-y RFS: baseline SUV_max (primitive tumor [T]) (hazard ratio [HR], 1.05 [95% CI, 1.01–1.1; <em>P</em> = 0.018]), SUV_peak (T) (HR, 1.09 [95% CI, 1.02–1.15; <em>P</em> = 0.007]), MTV 41% (T) (HR, 1.02 [95% CI, 1–1.03; <em>P</em> = 0.023]), MTV 41% (lymph node [N]) (HR, 1.06 [95% CI, 1.03–1.1; <em>P</em> &lt; 0.001]), MTV 41% (T + N) (HR, 1.02 [95% CI, 1–1.03; <em>P</em> = 0.005]), and posttreatment SUV_max (HR, 1.21 [95% CI, 1.09–1.34; <em>P</em> &lt; 0.001]). <strong>Conclusion:</strong> Treatment response assessed by ¹⁸F-FDG PET/CT after RT for SCCA has a significant prognostic value.¹⁸F-FDG PET/CT could be useful for adapting follow-up, especially for patients with locally advanced-stage tumors. Quantitative parameters could permit identification of patients with a worse prognosis but should be evaluated in further trials.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"138 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141462405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [177Lu]Lu-PSMA-I&T Therapy","authors":"Sandra Resch, Sibylle I. Ziegler, Gabriel Sheikh, Lena M. Unterrainer, Mathias J. Zacherl, Peter Bartenstein, Guido Böning, Julia Brosch-Lenz, Astrid Delker","doi":"10.2967/jnumed.123.266871","DOIUrl":"https://doi.org/10.2967/jnumed.123.266871","url":null,"abstract":"<p>Internal dosimetry supports safe and effective patient management during radionuclide therapy. Yet, it is associated with high clinical workload, costs, and patient burden, as patient scans at multiple time points (MTPs) must be acquired. Dosimetry based on imaging at a single time point (STP) has continuously gained popularity. However, MTP protocols, used as a reference to judge the validity of STP dosimetry, differ depending on local requirements and deviate from the unknown patient-specific ground truth pharmacokinetics. The aim of this study was to compare the error and optimum time point for different STP approaches using different reference MTP protocols. <strong>Methods:</strong> Whole-body SPECT/CT scans of 7 patients (7.4–8.9 GBq of [¹⁷⁷Lu]Lu-PSMA-I&amp;T) were scheduled at 24, 48, 72, and 168 h after injection. Sixty lesions, 14 kidneys, and 10 submandibular glands were delineated in the SPECT/CT data. Two curve models, that is, a mono- and a biexponential model, were fitted to the MTP data, in accordance with goodness-of-fit analysis (coefficients of variation, sum of squared errors). Three population-based STP approaches were compared: one method published by Hänscheid et al., one by Jackson et al., and one using population-based effective half-lives in the mono- or biexponential curve models. Percentage differences between STP and MTP dosimetry were evaluated. <strong>Results:</strong> Goodness-of-fit parameters show that a monoexponential function and a biexponential function with shared population-based parameters and physical tail are reasonable reference models. When comparing both reference models, we observed maximum differences of −44%, −19%, and −28% in the estimated absorbed doses for lesions, kidneys, and salivary glands, respectively. STP dosimetry with an average deviation of less than 10% from MTP dosimetry may be feasible; however, this deviation and the optimum imaging time point showed a dependence on the chosen reference protocol. <strong>Conclusion:</strong> STP dosimetry for [¹⁷⁷Lu]Lu-PSMA therapy is promising to boost the integration of dosimetry into clinical routine. According to our patient cohort, 48 h after injection may be regarded as a compromise for STP dosimetry for lesions and at-risk organs. The results from this analysis show that a common gold standard for dosimetry is desirable to allow for reliable and comparable STP dosimetry.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141462424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate-Specific Membrane Antigen–Targeted Imaging and Its Correlation with HOXB13 Expression","authors":"Duminduni Hewa Angappulige, Nimrod S. Barashi, Nicholas Pickersgill, Cody Weimholt, Jingqin Luo, Ghazal Shadmani, Ziad Tarcha, Sampanna Rayamajhi, Nupam P. Mahajan, Gerald L. Andriole, Barry A. Siegel, Eric H. Kim, Kiran Mahajan","doi":"10.2967/jnumed.123.267301","DOIUrl":"https://doi.org/10.2967/jnumed.123.267301","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.123.267301absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"180 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141462518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Radiosynoviorthesis: A Prospective Canadian Multicenter Study","authors":"Mélanie Desaulniers, Michel Paquette, Stéphanie Dubreuil, Helena Senta, Éric Lavallée, J. Carter Thorne, Éric Turcotte","doi":"10.2967/jnumed.123.267297","DOIUrl":"https://doi.org/10.2967/jnumed.123.267297","url":null,"abstract":"<p>Radiosynoviorthesis is approved in several European countries and the United States to treat refractory synovitis in many inflammatory joint diseases, such as rheumatoid arthritis, spondyloarthropathies, and other arthritic joint diseases. No radiopharmaceuticals for radiosynoviorthesis are currently approved in Canada. The aim of this Health Canada–approved trial was to demonstrate the safety and efficacy of radiosynoviorthesis. <strong>Methods:</strong> Between July 2012 and November 2017, we conducted a multicenter, prospective, interventional Canadian trial. Patients (<em>n</em> = 360) with synovitis refractory to standard treatments after failing 2 intraarticular glucocorticoid injections were included. They were followed up at 3, 6, and 12 mo. Outcome measures included adverse events (AEs) and clinical signs of synovitis (pain, swelling, and joint effusion) measured with the Health Assessment Questionnaire Disability Index, the Disease Activity Score, and the Visual Analog Scale. <strong>Results:</strong> In total, 392 joints were treated, including those reinjected after 6 mo (<em>n</em> = 34). Of these, 83.4% (327/392) were injected with [⁹⁰Y]Y-citrate for the knees and 9.9% (39/392) with [¹⁸⁶Re]Re-sulfide for medium-sized joints. Of the joints treated, 82.7% (324/392) were knees. Fifty-five AEs, most of them of mild grade, occurred and resolved without sequelae and were not life-threatening. The incidence of radiosynoviorthesis-related AEs was 9.4% (34/360). The proportion of patients showing an improvement in synovitis symptoms after radiosynoviorthesis was significant at 3 mo and was maintained up to 12 mo (<em>P</em> &lt; 0.001). <strong>Conclusion:</strong> This study confirmed the safety of radiosynoviorthesis in the treatment of patients with synovitis refractory to standard treatments. There is evidence of sustained clinical efficacy at 12 mo, suggesting that radiosynoviorthesis is an effective treatment for improving synovitis symptoms.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140953718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}